Inställningar

Split view

Short keys for navigating in split view

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Dark Mode

Set dark mode to MFN.se

Sound

Plays a notification sound when new press release is published in the current feed

08:46:15 Europe / Stockholm

Svenska | English

BioStock

BioStock: SynAct Pharma's CEO provides an update

2024-05-02 09:22:47

SynAct Pharma has signed a contract with a CRO and aims to submit a Clinical Trial Application this quarter for the upcoming clinical phase IIb study with resomelagon. Furthermore, the company has conducted a capital raise of SEK 49 million, and the new board and management team are working to reduce costs.
- Together, the new team is more focused and ready to move fast, says CEO Jeppe Øvlesen.

Read the full article at biostock.se (https://www.biostock.se/en/):

https://www.biostock.se/en/2024/05/synact-pharmas-ceo-provides-an-update/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

BioStock

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden